Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, you can stop Wegovy after reaching your weight-loss goal, but stopping it is not a simple off-switch. Most people who discontinue semaglutide regain a significant portion of the weight they lost, because the medicine is treating an ongoing biological condition rather than fixing it permanently. Whether you stop now or later is a clinical decision worth making with a prescriber who knows your full picture. These are prescription-only medicines, and any plan around continuing, pausing or ending treatment should be discussed with a qualified clinician.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 extension study followed participants who had lost weight on semaglutide 2.4mg and then stopped. Within a year of discontinuation, they had regained roughly two-thirds of the weight they had lost during the 68-week treatment period, as reported in the STEP 1 trial, published in the New England Journal of Medicine. Cardiometabolic markers that had improved during treatment (blood pressure, blood sugar, cholesterol) also shifted back toward baseline.
This happens because semaglutide works by reducing appetite signals and slowing gastric emptying. When you stop injecting, those effects fade over a few weeks as the drug clears your system. The biological drivers of weight (hormones like ghrelin that push appetite upward) reassert themselves. Your body's weight-regulating system did not change permanently; the medicine was doing the regulating on its behalf.
That is not an argument against stopping. It is an argument for planning. People who have built strong habits around food, protein intake and regular activity during treatment tend to regain less, though the clinical literature is consistent that regain happens for most people to some degree. Our wegovy articles cover the research behind this in more detail, and understanding what weight loss looks like after Wegovy ends is worth reading before you make the call.
Yes, and it is specific. NICE's technology appraisal TA875 recommends semaglutide for weight management for a maximum of two years, used within a specialist service that includes multidisciplinary support. The guidance also says that if someone has not lost at least 5% of their body weight after six months on the full maintenance dose, the prescriber should review whether continuing makes sense.
In practice this means that NICE frames stopping as a normal part of the treatment plan, not a last resort. A two-year course is the upper limit recommended, not a target everyone must hit. The right stopping point for you depends on how much weight you have lost, your current health conditions, and how well your lifestyle changes have bedded in.
For those accessing treatment privately, the two-year ceiling is still clinically relevant, it reflects the evidence base for long-term safety and effectiveness. Every repeat order at our pharmacy involves a clinical review, so any concerns about when to stop can be raised at that point rather than guessed at alone.
There is no MHRA-mandated tapering schedule for semaglutide in the way there is for some other medicines, but stopping from a high maintenance dose abruptly versus stepping down is something worth discussing with your prescriber rather than deciding unilaterally. Some clinicians prefer a gradual step-down to manage the return of appetite more gently; others take a different view depending on the patient's situation.
The honest answer is that the evidence base for tapering specifically is limited, and the NHS medicines information for semaglutide directs readers to follow prescriber guidance rather than self-directing this decision. If you are thinking about stopping after one month rather than a longer course, it is worth reading about stopping Wegovy after just one month, because the clinical picture at that stage is different from stopping after sustained weight loss.
Practically, if you are heading into a holiday or a busy patch (say you want to pause over the summer before restarting in September) that conversation belongs with your prescriber too. A pause is not automatically harmful, but it is not neutral either, and restarting after a break may affect how your body responds to the medicine initially.
Stopping Wegovy successfully is less about the injection schedule and more about what is in place when the appetite-suppressing effect lifts. Most clinicians would want to see solid protein habits (adequate intake at each meal slows the return of hunger), a sustainable activity routine, and realistic expectations about some degree of weight regain without treating it as a catastrophe. If you are considering stopping Wegovy after weight loss, our dedicated guide walks through what to expect and how to prepare practically.
It is also worth knowing that appetite tends to return gradually rather than crashing back overnight, which gives a window to reinforce habits before hunger is back to its pre-treatment baseline. Some people find that weight loss plateauing on Wegovy while still on the medicine is actually a signal that they are approaching the right stopping conversation, rather than a reason to increase the dose.
If you are weighing up your options, understanding what Wegovy weight loss after 1 month typically looks like can help you judge whether you are at an early stage where more time on treatment would be beneficial, or genuinely ready to stop. A free consultation through our treatment page connects you with a GPhC-registered prescriber who can review your current situation and help you think through timing properly. There is no pressure toward any particular outcome. The right answer depends on your health, not on continuing indefinitely.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.